Filing Flows › Sanara MedTech (SMTI) › Q2 2025
Sanara MedTech (SMTI) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 13, 2025
Sanara MedTech (SMTI) reported revenue of $25.8M for the second quarter 2025 (Q2 2025), +28% from a year earlier and +10% from the quarter before. Operating margin was -0.1%, net loss $2.0M (7.8% of revenue).
Sanara MedTech, Q2 2025: revenue $25.8M (+28% year over year), operating margin -0.1%, net loss $2.0M, operating cash flow $2.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $25.8M | +10% | +28% |
| Operating profit | −$31K | — | — |
| Net earnings | −$2.0M | — | — |
| Operating cash flow | $2.7M | — | — |
| Free cash flow | $903K | — | — |
What changed
Revenue was $25.8M in Q2 2025, up 28% year over year and up 10% from the previous quarter. Soft Tissue Repair Products was the largest line at 88% of revenue. Soft Tissue Repair Products added $5.0M year over year (up 28%), 89% of the total change.
Gross margin was 92.5%, up 2.5 points from a year earlier. Operating costs exceeded revenue by $31K, an operating margin of -0.1%. Operating expenses grew 14% against revenue growth of 28%. The fastest-growing cost line was Research & development (+28%). The quarter ended with a net loss of $2.0M, narrower than the previous quarter's $3.5M loss. Net interest and other expense of $2.0M was the main reason.
Operating cash flow was $2.7M. Non-cash charges added back $1.1M of depreciation and amortization and $1.4M of share-based compensation. Working capital and other items added $2.1M. Capital expenditures of $1.8M left free cash flow of $903K.
Questions
What was Sanara MedTech's revenue in the second quarter 2025?
Sanara MedTech (SMTI) reported revenue of $25.8M for the second quarter 2025 (Q2 2025), +28% from a year earlier and +10% from the quarter before.
Was Sanara MedTech profitable in the second quarter 2025?
Operating loss was $31K (-0.1% of revenue) and net loss $2.0M.
Source: Sanara MedTech 10-Q on SEC EDGAR.